Skip to main content

Table 1 Baseline characteristics

From: Safety and feasibility of oral immunotherapy to multiple allergens for food allergy

  Multiple food allergy group Single peanut allergy group
Number of participants 25 15
Median Age in yrs. (range) 8 (4–25) 10 (5–46)
Male 14 (56%) 8 (53%)
Coexisting atopic disease
 Atopic Dermatitis 17 (68%) 8 (53%)
 Allergic Rhinitis 13 (52%) 9 (60%)
 Asthma 17 (68%) 10 (66%)
Baseline testing to peanut (median and range)
 SPT in mm 15 (7–25.5) 12 (7–22)
 Specific IgE in kUA/L 90.4 (2.43-100) 80 (3.66-100)
 DBPCFC step eliciting symptoms (mg protein) 50 (0.1-100) 25 (1.6-100)
Symptoms upon peanut DBPCFC
 Skin 20 (80%) 12 (80%)
 Upper airways 18 (72%) 12 (80%)
 GI 17 (68%) 12 (80%)
 Lower airways 6 (24%) 3 (20%)
Other food allergies meeting DBPCFC criteria for inclusion
 Walnut 14 (56%) N/A
 Cashew 13 (52%) N/A
 Pecan 7 (28%) N/A
 Milk 7 (28%) N/A
 Egg 6 (24%) N/A
 Sesame 6 (24%) N/A
 Almond 5 (20%) N/A
 Hazelnut 3 (12%) N/A
Number of food in mix
 2 6 (24%) N/A
 3 8 (32%) N/A
 4 5 (20%) N/A
 5 6 (24%) N/A